Model DetailsEye - Harderian gland adenoma
Model Name |
Eye - Harderian gland adenoma | Strain |
(C57BL/6N x C3H/HeN)F1 |
Tumor Inducing Agent(s) |
None (spontaneous) |
Tumor Synonyms |
Harderian adenoma • special senses eye lacrimal and/or Harderian gland adenoma • Harderian gland adenoma |
Strain Synonyms |
BCF1 • B6C3F1 • C57BL/6NxC3H/HeN F1 • B6C3F1 • (C57BL/6N X C3H/HeN)F1 |
| Organ Affected | Sex | Frequency | Age Of Detection | Additional Information Expand all Collapse all | Reference |
|---|---|---|---|---|---|
| Eye - Harderian gland | Male |
2.5% (6 of 244 mice) |
2 years |
|
Tamano S, Toxicol Pathol 1988;16(3):321-6 |
| Eye - Harderian gland | Female |
2.8% (7 of 246 mice) |
2 years |
|
Tamano S, Toxicol Pathol 1988;16(3):321-6 |
| Eye - Harderian gland | Female |
6.7% (1 of 15 mice) |
30 months |
|
Sheldon WG, Toxicol Pathol 1995 Jul-Aug;23(4):458-76 |
| Eye - Harderian gland | Female |
35.7% (5 of 14 mice) |
36 months |
|
Sheldon WG, Toxicol Pathol 1995 Jul-Aug;23(4):458-76 |
| Eye - Harderian gland | Female |
3.1% (1 of 32 mice) |
24 +/- 3 months |
|
Sheldon WG, Toxicol Pathol 1995 Jul-Aug;23(4):458-76 |
| Eye - Harderian gland | Female |
6.8% (5 of 73 mice) |
30 +/- 3 months |
|
Sheldon WG, Toxicol Pathol 1995 Jul-Aug;23(4):458-76 |
| Eye - Harderian gland | Female |
21.1% (4 of 19 mice) |
36 +/- 3 months |
|
Sheldon WG, Toxicol Pathol 1995 Jul-Aug;23(4):458-76 |
| Eye - Harderian gland | Female |
9.1% (2 of 22 mice) |
30 +/- 3 months |
|
Sheldon WG, Toxicol Pathol 1995 Jul-Aug;23(4):458-76 |
| Eye - Harderian gland | Male |
13.3% (2 of 15 mice) |
36 months |
|
Sheldon WG, Toxicol Pathol 1995 Jul-Aug;23(4):458-76 |
| Eye - Harderian gland | Male |
5.3% (1 of 19 mice) |
24 +/- 3 months |
|
Sheldon WG, Toxicol Pathol 1995 Jul-Aug;23(4):458-76 |
| Eye - Harderian gland | Male |
6.4% (3 of 47 mice) |
30 +/- 3 months |
|
Sheldon WG, Toxicol Pathol 1995 Jul-Aug;23(4):458-76 |
| Eye - Harderian gland | Male |
17.6% (6 of 34 mice) |
36 +/- 3 months |
|
Sheldon WG, Toxicol Pathol 1995 Jul-Aug;23(4):458-76 |
| Eye - Harderian gland | Male |
28.6% (2 of 7 mice) |
42 +/- 3 months |
|
Sheldon WG, Toxicol Pathol 1995 Jul-Aug;23(4):458-76 |
| Eye - Harderian gland | Male |
12.5% (1 of 8 mice) |
24 +/- 3 months |
|
Sheldon WG, Toxicol Pathol 1995 Jul-Aug;23(4):458-76 |
| Eye - Harderian gland | Male |
4.8% (1 of 21 mice) |
30 +/- 3 months |
|
Sheldon WG, Toxicol Pathol 1995 Jul-Aug;23(4):458-76 |
| Eye - Harderian gland | Male |
12.5% (2 of 16 mice) |
36 +/- 3 months |
|
Sheldon WG, Toxicol Pathol 1995 Jul-Aug;23(4):458-76 |
| Eye - Harderian gland | Male |
0.75% (19 of 2543 mice) |
94-114 weeks |
|
Ward JM, J Natl Cancer Inst 1979 Sep;63(3):849-54 |
| Eye - Harderian gland | Female |
0.44% (11 of 2522 mice) |
94-114 weeks |
|
Ward JM, J Natl Cancer Inst 1979 Sep;63(3):849-54 |
| Eye - Harderian gland | Mixed Population |
0.59% (30 of 5065 mice) |
94-114 weeks |
|
Ward JM, J Natl Cancer Inst 1979 Sep;63(3):849-54 |